<SEC-DOCUMENT>0001493152-17-006352.txt : 20170609
<SEC-HEADER>0001493152-17-006352.hdr.sgml : 20170609
<ACCEPTANCE-DATETIME>20170609074746
ACCESSION NUMBER:		0001493152-17-006352
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170609
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170609
DATE AS OF CHANGE:		20170609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		17901500

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif; margin-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): June 9, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission
        </B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
        Number)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25
Recreation Park Drive, Unit 108</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hingham,
Massachusetts 02043</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Offices) (Zip Code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (908)938-5561</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[&nbsp;&nbsp;]</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[&nbsp;&nbsp;]</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[&nbsp;&nbsp;]</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01. Other Events.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 9, 2017, the Company issued a press release titled &ldquo;Microbot Medical Announces Closing of $10 Million Registered Direct
Offering of Common Stock.&rdquo; A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference
into this Item 8.01 of this Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No. </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release dated June 9, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Harel Gadot</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 9, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I><IMG SRC="image_001.jpg" ALT=""></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Announces Closing of $10 Million Registered Direct Offering of Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hingham,
MA &ndash; June 9, 2017 &ndash; Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and
development of transformational micro-robotic medical technologies, closed its previously announced registered direct offering
of 3,750,000 shares of common stock for total gross proceeds of $10.125 million, before deducting placement agent fees and offering
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to use the resources from the financing to expand and leverage the current ViRob and TipCAT technology platforms,
for potential strategic partnerships and acquisition of assets, products or entities, and for general corporate and working capital
purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg
Thalmann &amp; Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS), acted as the lead placement
agent and Chardan acted as the co-placement agent for this transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares were offered by the Company pursuant to an effective &ldquo;shelf&rdquo; registration statement which was initially filed
with the Securities and Exchange Commission on March 31, 2017 and declared effective by the SEC on April 14, 2017. The securities
were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
Copies of the final prospectus supplement and accompanying base prospectus may be obtained at the SEC&rsquo;s website at www.sec.gov
or from Ladenburg Thalmann &amp; Co. Inc., Prospectus Department, 277 Park Avenue, 26<SUP>th</SUP> Floor, New York, NY 10172 or
by email at <U>prospectus@ladenburg.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any
sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by
means of a prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
was founded in 2010 and became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic
medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s current platforms, ViRob
and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its
first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus,
or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.
Further information about Microbot Medical is available at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature
dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract
and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the
ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT
is a transformational self-propelled, flexible, and semi-disposable endoscope providing see &amp; treat capabilities within tubular
lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable
to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve the
adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and
ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that
affect the businesses of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical
Inc.&rsquo;s filings with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update
these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contacts: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Analysts
and Institutional Investors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">646-445-4800</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Individual
&amp; Retail Investors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy
Roe</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integra
Consulting Group llc</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jeremy@integracg.net</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(925)
262-8305</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !3 -X# 2(  A$! Q$!_\0
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M;NY2QBN;V2.TCN+N[GCA5(YKFXD5IG]+4DC)QWZ'(QDX(.!U'/3CI0!\,_\
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M/XE +* AM=2(4!64 *#M& !@#()R3^S7_!,_Q&GA/_@F7X,\5R6XGA\+Z?\
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M5P7$/#V-CGN0YBXNZ>#S.A&AB,IJ*"DJV0<09=E&;TIJ4J%/,,/0J8M?NO\
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MV""-8]);6_A3>6]G'&JHD-E_:/P@O6LD6)1#$]FUM/##M$<HD424 ?1'P_\
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M8H)+W5?#NK:79HY\N.2\U;2]2TZU26<Y6WB^T3Q>9,R.(U/*'<, '\\?AO\
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MXR%Q/X@T+PG;3:K;:]IG]O3:EJ4\J>*/!^KRZ7<:G?6]EJ-]:0V.H2;>J?\
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M?302*492OS1(B$XSA5((*@@HH O)$C$MAE;]VQ9'>-FP"X#&-E+(&D<A&)0
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DRYP,*  44 6(E"[PHP,J<#H,J"<>@R3@#@=   !4M%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
